Bone resorption in multiple myeloma;L'hyperresorption osseuse au cours du myelome multiple

Presse Medicale

Volumn 29, Issue 9, 2000, Pages 492-497

  Beaudreuil, J ^a   Orcel, Ph ^a  

^a CENTRE VIGGO PETERSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CELL ADHESION MOLECULE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6;

BONE DESTRUCTION; DISEASE MARKER; DRUG EFFECT; HUMAN; HYPERCALCEMIA; MORPHOMETRICS; MULTIPLE MYELOMA; OSTEOLYSIS; REVIEW; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MULTICENTER STUDY; OSTEOCLAST; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; BONE RESORPTION; CONTROLLED CLINICAL TRIALS; CYTOKINES; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; INTERLEUKIN-1; INTERLEUKIN-6; MULTICENTER STUDIES; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0034635893     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Bartl R, Frisch B, Fateb-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective study of 674 cases. Am J Clin Pathol 1987 ; 87:342-55.
2. Kyle RA. Multiple myeloma. Review of 869 cases. Mayo Clin Proc 1975 ; 50:29-40.
3. Rossi JF, Bataille R, Chappard D, Alexandre C, Janbon C. B Cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Am J Med 1987 ; 83:10-16.
4. Beaudreuil J, Lortholary O, Martin A et al. Hypercalcemia may indicate Richter's syndrome : report of four cases and review. Cancer 1997 ; 79:1211-15.
5. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982 ; 52:601-10.
6. Grauer JL, Blanc D, Zagala A et al. L'histomorphométrie osseuse dans les dysglobulinémies moroclonales. Intérèt diagnostique et pronostique. Rev Rhum, 1986 ; 53:517-23.
7. Bataille R, Chappard D, Alexandre C, Dessauw P, Sany J. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 1986 ; 53:805-10.
8. Bataille R, Chappard D, Marcelli C et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989 ; 7:1909-14.
9. Bataille R, Chappard D, Marcelli C et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991 ; 88:62-6.
10. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodeling n patients with myelomatosis and normal biochemical indices of bone resorpton. Eur J Haematol 1992 49:192-8.
11. Cohen-Solal M, Roux Ch, Valentin-Opran A, Dougados M, Amor B, de Vernejoul MC. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone 1993 ; 14:505-9.
12. Roux C, Ravaud P, Cohen-Solal M et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994 ; 15:41-9.
13. Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies Blood 1996 ; 87:4762-9.
14. Laroche M, Attal M, Dromer C and the Midi-Pyrénées Myeloma Group. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol 1996 ; 15:347-52.
15. Diamond T, Day LP, Barbagallo S, Manoharan A, Kwan YK. Biochemical, histomorphometric and densitometric changes n patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 1997 ; 97:641-8
16. Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Onc Clin North Am 1997 ; 11:349-61.
17. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992 ; 340:1049-52.
18. Heim ME, Clemens MR, Queisser W et al Prospective randomized trial of dichloromethylene bisphosphonate (dodrorate) in patients with multiple myeloma requiring treatment a multicenter stucy. Onkologie 1995 ; 18:439-48.
19. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996 ; 334:488-93.
20. Berenson JR, Lichtenstein A, Porter A, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998 : 16:593-602.
21. McCloskey EV, McLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma Br J Haematol 1998 ; 100:317-25.
22. de Vernejoul MC, Marie P. Remodelage osseux et cellules osseuses. In: Maladies métaboliques osseuses de l'adulte. Kuntz D éd. Médecine-Sciences, Flammarion, Paris, 1996, 3-16.
23. Mundy GR, Raisz LG, Coopet RA, Schechter GP, Salmon SE. Evidence for the secreton of an osteoclast stimulating factor in myeloma. N Engl J Med 1974 ; 291:1041-6.
24. E'omaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992 ; 66:337-41.
25. Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol 1994 ; 46:173-8.
26. Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. Clinica Acta Chimica 1996 ; 253:61-77.
27. Peest D, Deicher H, Fett W et al. Pyridinium Cross-links in multiple myeloma/ correlation with clinical parameters and use for monitoring of intravenous clodronate therapy-a pilot study of the German Myeloma Treatment Group (GMTG), Eur J Cancer 1996 ; 32A:2053-7.
28. Seibel MJ, Woitge HW, Pecherstorfer M et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996 ; 81:3289-94.
29. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff Serum markers of bone metabolism n multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haematol 1997 ; 96:103-10.
30. Pecherstorfer M, Seibel M, Woitge HW et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997 ; 90:3743-50.
31. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorpton markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999 ; 62:300-6.
32. Woitge HW, Pecherstorfer M, Li Y et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14:792-801.
33. Garnero P, Delmas PD. Marqueurs biochimiques du remodelage osseux. In: Maladies métaboliques osseuses de l'aculte Kuntz D ed. Médecine-Sciences, Flammarion, Paris, 1996, 99-111
34. Chappard D, Rossi JF, Bataille JF, Alexandre C. Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma. Calcif Tissue Int 1991 ; 48:13-17
35. Bataille R, Chappard D. Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 1995 ; 90:721-4.
36. Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell D. Bone-resorbing activity in supernatants from lymphoic cell lines. N Eng J Med '974 ; 290:867-71.
37. Garrett IR, Durie BGM, Nedwin GE et al. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987 ; 317:526-32.
38. Kawano M, Hirano T, Matsuda T et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988 ; 332:83-5.
39. Cozzolino F, Torcia M, Aldinucci D et al. Production of interleukin-1 by marrow myeloma cells Blood 1989 ; 74:380-7.
40. Kawano M, Yamamoto I, Iwato K et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989 ; 73:1646-9.
41. Klein B, Zhang XG, Jourdan M et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989 ; 73:517-26.
42. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989 ; 74: 1266-73.
43. Yamamoto I, Kawano M, Sone T et al. Production of interleukin 1β, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res 1989 ; 49:4242-6.
44. Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol 1993 ; 85:446-51
45. Roodman GD. Interleukin-6: an ostectropic factor? J Bone Miner Res 1992 : 7:475-8.
46. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-depived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993 ; 82:3712-20.
47. Lokhorst HM, Lamme T, de Smet M et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994 ; 84:2269-77.
48. Barillé S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86:3151-9.
49. Chauhan D, Uchiyama H, Akbarali Y et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stremal cells involves activation of NF-κB. Blood 1996; 87:1104-12.
50. Bloem A, Lamme T, de Smet M et al. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. Br J Haematol 1998 ; 100:166-75.
51. Costes V, Portier M, Lu ZY, ROSSI JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998 ; 103:1152-60
52. Shimizu S, Yoshioka R, Hirose Y, Sugai S, Tachibana J, Konda S. Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon β2)-dependent human bone marrow-derived myeloma cell lines. J Exp Med 1989 ; 169:339-44.
53. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. lnterleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995 ; 162:248-55.
54. Xu FH, Sharma S, Gardner A et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the NK/SAPK pathway. Blood 1998 ; 92241-51.
55. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease seventy in plasma cell dyscrasias. J Clin Invest 1989 ; 84:2008-11.
56. Ludwig H, Nachbaut DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991 ; 77:2794-5.
57. Jernberg-Wiklund H, Petterson M, Carlsson M, Nilsson K. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, during longterm in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 1992 ; 6:310-18.
58. Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993 ; 90:11924-8.
59. Gaillard JP, Bataille R, Brailly H et al. Increased and highly stable levels of functionnal soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993 ; 23:820-4.
60. Schneider HG, Kartsogiannis V, Zhou H, Chou ST, Martin TJ, Grill V. Parathyroid hormone-related protein mRNA and protein expression in multiple myeloma : a case report. J Bone Miner Res 1998 ; 13:1640-3.
61. Bataille R, Chappard D, Marcelli C et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 1990 ; 76:484-7.
62. Bataille R, Delmas P, Chappard D, Sany J. Abnormal serum bone gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications Cancer 1990 ; 66: 167-72
63. Mejjad O, Le Loet X, Basuyau JP et al. Osteocalcin is not a marker of progress in multiple myeloma Eur J Haematol 1996; 56:30-4.
64. Marie P, de Vernejoul MC. Facteurs systémiques et locaux du remodelage osseux. In: Maladies métaboliques osseuses de l'adulte. Kuntz D ed. Médecine-Sciences, Flammarion, Paris, 1996, 49-68.
65. Acute Leukemia Group B and the Eastern Cooperative Oncology Group Ineffectiveness of fluoride therapy in multiple myeloma. N Engl J Med 1972 ; 286:1283-8.
66. Cohen JH, Silberman HR, Tornyos K, Bartolucci AA. for the Southeastern Cancer Study Group (SECSG). Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma Blood 1984 ; 63:639-48.
67. Fleish H. Bisphosphonates mechanisms of action. Endocrine Rev 1998 ; 19:80-100.
68. Hughes DE, Mc Donald BR, Russell RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989 : 83: 1930-5.
69. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclas: ultrastructure. J Clin Invest 1991 ; 88:2095-105.
70. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995 ; 10:1478-87.
71. Breuil V, Cosman F, Stein L et al. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 1998 : 13: 1721-9.
72. Tokuda H, Kozawa O, Harada A, Uematsu T. Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3 cells J Cell Biochem 1998 ; 69:252-9.
73. Shipman CM, Rogers MJ, Apperley F et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997 : 98:665-72.
74. Gordon S, Helfrich MH, Sati HIA et al. Pamidronate and myeloma cell apoptosis: results of an in vivo study. J Bone Miner Res 1999 ; 14(suppl 1):SI63.
75. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer 1995 ; 72:1289-93.
76. Ralston SH, Thiébaud D, Hermann Z et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1997 ; 75:295-300.
77. Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991 ; 9:1397-402.
78. Brincker H, Westin J, Abildgaard N et al. Failure of oral pamidronate to reduce skeletal morbidity n multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998 ; 101:260-6.
79. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metatstatic carcinoma of the breast to bone. Bone 1991 : 12(suppl 1):S37-S42.
80. Bruce NJ, McCloskey EV, Kanis JA, Guest JF. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 1999 104:358-64.